COGENT BIOSCIENCES INC (COGT)
US19240Q2012 - Common Stock
COGENT BIOSCIENCES INC
NASDAQ:COGT (12/18/2024, 1:25:05 PM)
7.91
-0.28 (-3.42%)
Company Profile
Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. The company is headquartered in Waltham, Massachusetts and currently employs 164 full-time employees. The company went IPO on 2018-03-29. The firm is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.
Company Info
COGENT BIOSCIENCES INC
275 Wyman Street, 3rd Floor
Waltham MASSACHUSETTS 02140
P: 16179455576
CEO: Andrew Robbins
Employees: 164
Website: https://www.cogentbio.com/
COGT News
5 days ago - Market News VideoCogent Biosciences Becomes Oversold (COGT)
8 days ago - ChartmillWhich stocks are moving after the closing bell on Tuesday?As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
9 days ago - Yahoo FinanceWhy Is Cogent Biosciences Stock Trading Higher On Monday?On Sunday, Cogent Biosciences, Inc. (NASDAQ:COGT) revealed updated clinical results from the Open Label Extension (OLE) portion of the SUMMIT trial of bezuclastinib in patients with non-advanced systemic mastocytosis. Non-advanced systemic mastocytosis is a rare disease that involves mast cell buildup in tissues and organs. Updated clinical data presented at the American Society of Hematology Annual Meeting & Exposition show: 56% mean improvement in Total Symptom Score (TSS) at 24 weeks. 76% of
9 days ago - ChartmillCurious about the stocks that are showing activity before the opening bell on Monday?Get insights into the top gainers and losers of Monday's pre-market session.
9 days ago - Cogent Biosciences, Inc.Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients56% mean improvement in Total Symptom Score (TSS) at 24 weeks with 76% of patients achieving at least a 50% reduction in TSS 89% of...
10 days ago - Cogent Biosciences, Inc.Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg...
COGT Twits
Here you can normally see the latest stock twits on COGT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
